Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 15/20 | 0.48 |
| ▸ | AKT2 | P31751 | 11/20 | 0.48 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255818 | 0.95 | AKT1 (0.54) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5256580 | 0.93 | AKT1 (0.47) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5240266 | 0.91 | AKT1 (0.49) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5260308 | 0.90 | AKT1 (0.56) | AKT1AKT2AKT3KCNH2 | |
| SCHEMBL5263196 | 0.90 | AKT1 (0.53) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5333213 | 0.90 | AKT1 (0.56) | AKT1AKT2AKT3KCNH2 | |
| SCHEMBL5258032 | 0.90 | AKT1 (0.53) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5258255 | 0.89 | AKT1 (0.44) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5262509 | 0.89 | AKT1 (0.44) | AKT1AKT2AKT3PAX8HTR2B | |
| SCHEMBL5255697 | 0.88 | DRD2 (0.49) | AKT1AKT2AKT3PAX8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1494676-A4 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1494676-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | claimed |
| WO-2003086404-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | claimed |
| EP-1494676-A4 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1494676-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086404-A1 | FUSED QUINOXALINE DERIVATIVES AS INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |